|Day Low/High||155.10 / 159.07|
|52 Wk Low/High||112.60 / 172.18|
Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.
Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.
Today there was a virtual vacuum of good news in the stock market.
Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.
Pfizer shares were slipping after the drugmaker posted a premarket earnings whiff.
Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.
I continue to believe downside risks far outweigh the risks of a near-term rally.
In a "take no pain, take no prisoners" market, health care stocks languish.
We used this week's declines to add to our positions in Teligent, Builders FirstSource and Sonus Networks.
Shares of the drug distributor were falling sharply Friday.
The drugmaker's shares were hammered Friday on news that the industry is slashing prices.
Hershey shares got an early Halloween treat Friday after earnings topped analyst forecasts.
McKesson's disappointing earnings report ignited a selloff in health care stocks, and Jim Cramer says investors are questioning the sector's future.
The pricing structure of the healthcare and drug distribution industry has been wrecked and Wall Street is taking down those stocks as a result, says Jim Cramer.
Energy and consumer defensive names dominate on the bearish side.
Keep your powder dry and see if MCK tries to makes a double bottom.
McKesson is down 10 percent year-to-date due to the heated political debate over drug pricing but the stock is too cheap to ignore.
In the case of McKesson, Value Line system doesn't do investors any favors.
There are issues everywhere, in almost every group.
But try to have your buy orders below the market, in the $165 area.
Candidates have decried rising drug and medical prices, but there are reasons to like these stocks.
Undeterred by previous snubs, spicemaker McCormick makes a revised approach to Britain's Premier Foods, raising the proposed enterprise value to $2.16 billion.